GlassScriptPhysician profile
Vinh Nguyen
NPI 1881940369
$64,497.27
in general payments reported to CMS, 2019-2025
20 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $282 · 2021: $383 · 2022: $32K · 2023: $30K · 2024: $1,038 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $4,014 · Food and Beverage: $2,112 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,302.00 |
| Travel and Lodging | $4,013.70 |
| Food and Beverage | $2,112.01 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $61,648.12 | 2019-2025 | Camzyos, Eliquis |
| Celgene Corporation | $600.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $392.38 | 2020-2025 | Lokelma |
| Atricure, INC. | $353.38 | 2022 | |
| Pfizer INC. | $301.64 | 2019-2025 | |
| Amgen INC. | $198.13 | 2019-2021 | |
| Boston Scientific Corporation | $162.62 | 2019 | |
| Lantheus Medical Imaging, INC. | $157.48 | 2022-2025 | Definity |
| Janssen Pharmaceuticals, INC | $132.83 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $125.39 | 2020 | |
| Sanofi-Aventis U.S. LLC | $124.78 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.97 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $58.74 | 2025 | Onpattro |
| Esperion Therapeutics, INC. | $22.44 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $21.88 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agepha Pharma Fz LLC | $18.14 | 2024 | Lodoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.64 | 2025 | Jardiance |
| Bracco Diagnostics INC. | $16.00 | 2021 | |
| Scpharmaceuticals INC. | $15.97 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinh Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.